16.03.2018
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG in concluding negotiations for takeover of majority stake of enzyme producer Biocatalysts Ltd.
DGAP-Ad-hoc: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Investment/Mergers & Acquisitions
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG in
concluding negotiations for takeover of majority stake of enzyme producer
Biocatalysts Ltd.
16-March-2018 / 17:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN AG in concluding negotiations for takeover of majority stake of enzyme
producer Biocatalysts Ltd.
Zwingenberg, Germany
16 March 2018
Today, the bio-economy company BRAIN AG (together with its subsidiaries the
"BRAIN Group" or "BRAIN") announces that the signing of a share purchase
agreement between BRAIN and Biocatalysts Ltd. based in Cardiff, Great
Britain, and active in the field of speciality enzymes is in concluding
negotiations. Therein the takeover of the majority stake of Biocatalysts's
shares by BRAIN is governed. The transaction is planned to be completed
within the first quarter of 2018. The Supervisory Board of BRAIN AG was
informed about the process and granted its approval to the transaction.
Biocatalysts is a biotechnology company focused on the product development,
production and distribution of speciality enzymes for various industries
such as food and fine chemicals. BRAIN is a leading technology company in
the field of industrial biotechnology, developing microorganisms, natural
substances and enzymes for the industrial use.
The completion of the strategic acquisition of a majority stake in
Biocatalysts is intended to accelerate product driven growth in attractive
speciality enzyme markets, broaden the portfolio of the enzyme business of
BRAIN and achieve synergies with respect to research and development as well
as production and global distribution. After the expected completion of the
transaction, Biocatalysts Ltd. will continue to operate under the current
company name.
Biocatalysts Ltd. is profitable and generated revenues of approximately EUR
9.03 million* (£ 7.978 million) in the 2015/2016 financial year and. The
revenue for the financial year 2016/17 is
EUR 10.81 million* (£ 9,546 Mio.), which corresponds to a growth rate of
19.7% compared to the previous year. Biocatalysts Ltd.'s turnover has grown
by an compound annual growth rate (CAGR) of 12% between 2014/15 and 2016/17.
+++END+++
* Average Exchange Rate of February 2018: 1 GBP = 1.132 EUR (Source: Oanda)
Contact:
BRAIN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.de
IR Contact
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-(0)-6251-9331-16
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]
Media Contact
Thomas Deichmann
Head of Public Relations
Tel.: +49-(0)-6251-9331-72
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN
DE0005203947 / WKN 520394) is one of Europe's leading technology companies
in the field of industrial biotechnology, the core discipline of Bioeconomy.
As such, BRAIN identifies previously untapped, efficient enzymes, microbial
producer organisms or natural substances from complex biological systems
that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in
the chemistry, the cosmetics and the food industries. BRAIN's business model
is based on two pillars - BioScience and BioIndustrial. The BioScience
comprises its frequently exclusive collaboration business with industrial
partners. BioIndustrial comprises the development and commercialization of
BRAIN's own products and active product components. Further information is
available at www.brain-biotech.de/en.
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN group of companies. Such factors include, but are not
limited to, changes in the general economic and competitive environment,
risks associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.
---------------------------------------------------------------------------
16-March-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service
---------------------------------------------------------------------------
665255 16-March-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN